Terminated PHASE2 INTERVENTIONAL 1-arm NCT02090725

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) (3-4DAP)

Controlled Trial of 3,4-Diaminopyridine in LEMS

Sponsor: Jacobus Pharmaceutical

Updated 8 times since 2017 Last updated: May 1, 2019 Started: Feb 29, 2004 Primary completion: Jul 31, 2018 Completion: Nov 28, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Drug receive FDA approval

Other terminated trials from Jacobus Pharmaceutical

See all terminations from Jacobus Pharmaceutical

A PHASE2 clinical study on Muscle Weakness, this trial is terminated or withdrawn. The trial is conducted by Jacobus Pharmaceutical and has accumulated 8 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2019 — Jan 2021 [monthly]

Terminated PHASE2

Status: Enrolling By Invitation → Terminated · Phase: NA → PHASE2
Jul 2018 — Jun 2019 [monthly]

Enrolling By Invitation NA

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Enrolling By Invitation NA
Feb 2017 — Jun 2018 [monthly]

Enrolling By Invitation NA
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation NA

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jacobus Pharmaceutical
Jeffrey A. Cohen, MD

Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lebanon, United States